JP2005526051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526051A5 JP2005526051A5 JP2003572509A JP2003572509A JP2005526051A5 JP 2005526051 A5 JP2005526051 A5 JP 2005526051A5 JP 2003572509 A JP2003572509 A JP 2003572509A JP 2003572509 A JP2003572509 A JP 2003572509A JP 2005526051 A5 JP2005526051 A5 JP 2005526051A5
- Authority
- JP
- Japan
- Prior art keywords
- exo
- ptp
- mutated
- site
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36147502P | 2002-03-01 | 2002-03-01 | |
| US10/374,539 US6784205B2 (en) | 2002-03-01 | 2003-02-25 | Compounds that modulate the activity of PTP-1B and TC-PTP |
| PCT/US2003/005950 WO2003073987A2 (en) | 2002-03-01 | 2003-02-26 | Compounds that modulate the activity of ptp-1b and tc-ptp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526051A JP2005526051A (ja) | 2005-09-02 |
| JP2005526051A5 true JP2005526051A5 (https=) | 2006-04-13 |
Family
ID=27791680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572509A Withdrawn JP2005526051A (ja) | 2002-03-01 | 2003-02-26 | Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6784205B2 (https=) |
| EP (1) | EP1534264A4 (https=) |
| JP (1) | JP2005526051A (https=) |
| AU (1) | AU2003217766A1 (https=) |
| CA (1) | CA2477119A1 (https=) |
| WO (1) | WO2003073987A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2463724A1 (en) * | 2001-10-16 | 2003-04-24 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
| US6974681B1 (en) * | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| JP4898458B2 (ja) * | 2004-02-12 | 2012-03-14 | トランス テック ファーマ，インコーポレイテッド | 置換アゾール誘導体、組成物及び使用方法 |
| EP1765332A2 (en) * | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| WO2006017124A2 (en) * | 2004-07-09 | 2006-02-16 | Cengent Therapeutics, Inc. | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
| EP1841749A1 (en) * | 2004-09-02 | 2007-10-10 | Metabasis Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| BRPI0707338A2 (pt) | 2006-01-30 | 2011-05-03 | Transtech Pharma Inc | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase |
| WO2009091609A1 (en) * | 2008-01-18 | 2009-07-23 | Genaera Corporation | A method for treating rapamycin induced diabetes-like syndrome using trodusquemine |
| US9217012B2 (en) | 2009-04-08 | 2015-12-22 | Indiana University Research And Technology Corporation | Inhibitors of protein tyrosine phosphatases |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2014113407A2 (en) * | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| WO2018156553A1 (en) | 2017-02-21 | 2018-08-30 | Arizona Board Of Regents On Behalf Of Arizona State University | A method for targeted protein quantification by bar-coding affinity reagents with unique dna sequences |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703407B1 (en) * | 1994-09-20 | 2004-03-09 | Eli Lilly And Company | Benzofuran compounds, compositions, and methods |
| AU3791799A (en) * | 1998-05-12 | 1999-11-29 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| JP2003528106A (ja) * | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
| AU2001268951A1 (en) * | 2000-07-07 | 2002-01-21 | Novo-Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
-
2003
- 2003-02-25 US US10/374,539 patent/US6784205B2/en not_active Expired - Fee Related
- 2003-02-26 CA CA002477119A patent/CA2477119A1/en not_active Abandoned
- 2003-02-26 EP EP03713729A patent/EP1534264A4/en not_active Withdrawn
- 2003-02-26 JP JP2003572509A patent/JP2005526051A/ja not_active Withdrawn
- 2003-02-26 WO PCT/US2003/005950 patent/WO2003073987A2/en not_active Ceased
- 2003-02-26 AU AU2003217766A patent/AU2003217766A1/en not_active Abandoned
-
2004
- 2004-02-27 US US10/788,564 patent/US20040147596A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526051A5 (https=) | ||
| Izeboud et al. | The β-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-α and IL-6 in vitro and in vivo | |
| Hassell et al. | Drug-induced gingival overgrowth: old problem, new problem | |
| US20240261307A1 (en) | Inhibitors of sars-cov-2 viral replication and uses thereof | |
| JP6118273B2 (ja) | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 | |
| Marshall et al. | Medication induced gingival overgrowth | |
| US11845990B2 (en) | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | |
| Garlet et al. | Expression of suppressors of cytokine signaling in diseased periodontal tissues: a stop signal for disease progression? | |
| CZ330896A3 (cs) | Použití látky, která brání nebo minimalizuje oxidaci polynenasycené mastné kyseliny a způsoby s tímto použitím spojené | |
| BRPI0708347A2 (pt) | inibição jak2 como um tratamento da hipertensão arterial pulmonar | |
| JP2006514021A5 (https=) | ||
| ES2969532T3 (es) | 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico | |
| JP2019513010A (ja) | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 | |
| BR112021000060B1 (pt) | Derivados de 1,3,5-tris(6-metilpiridin-2-iloxi)benzeno e compostos relacionados como ligantes nlrx1 para tratar doenças inflamatórias | |
| CN108463221A (zh) | 吲哚类化合物刺激免疫系统的用途 | |
| JP2011515469A (ja) | シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療 | |
| CN1251993A (zh) | N－取代的1,5－二脱氧－1,5－亚氨基－d－山梨醇化合物在治疗肝炎病毒感染的联合疗法中的用途 | |
| JP2650039B2 (ja) | インターロイキン−１の放出を抑制する組成物 | |
| JP2005514440A5 (https=) | ||
| JP2007507472A5 (https=) | ||
| JP2023512062A (ja) | 関節の炎症を治療するためにモメロチニブを使用する方法 | |
| JP4874985B2 (ja) | 免疫調節化合物による出血性ウイルス感染の治療又は予防 | |
| WO2024054558A2 (en) | Compositions and methods for amelioration of symptoms associated with clec16a dysfunction or loss | |
| Reynolds | Loss of Chaperone Mediated Autophagy with Age Contributes to T Cell Immunosenescence | |
| Maki-Petaja et al. | Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society |